The current voluntary payment scheme for share fishermen was introduced to help customers with an uncertain earning pattern to save towards their income tax liability, which is accounted for and paid via the annual self-assessment (SA) process. The scheme is supported by Barclays, operating special bank accounts, from which HMRC can periodically withdraw funds.<\/p>
These arrangements no longer meet banking regulations. There has also been very low take-up of the voluntary payment scheme, so HMRC are working with Barclays to review what services can be offered to share fishermen in future, taking into account developments in the income tax self-assessment process and wider tax administration as well as the payment options available to other taxpayers.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"} } , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"} , "answeringMemberPrinted" : {"_value" : "Jesse Norman"} , "dateOfAnswer" : {"_value" : "2019-07-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-05T09:47:58.22Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2019-06-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Share Fishermen: Taxation"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Chancellor of the Exchequer, whether people participating in the Share Fisherman Scheme will be able to continue to participate in the scheme for the length of their working lives.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4657", "label" : {"_value" : "Biography information for Anneliese Dodds"} } , "tablingMemberConstituency" : {"_value" : "Oxford East"} , "tablingMemberPrinted" : [{"_value" : "Anneliese Dodds"} ], "uin" : "270381"} , {"_about" : "http://data.parliament.uk/resources/1135167", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135167/answer", "answerText" : {"_value" : "
There is no need to wait for a Universal Credit payment, as 100 per cent advances are available from day one of a claim. Advance payments are simply an advance of entitlement, meaning that by month 12 of a claim, a claimant would normally have received exactly the same Universal Credit regardless of whether they had an advance or not.<\/p>
<\/p>
Furthermore, frequency of payment should not affect the total amount of Universal Credit paid over the course of a year. Whilst legacy benefits were paid in two-weekly arrears, Universal Credit is paid in monthly arrears to help reduce welfare dependency by mirroring the world of work, where currently around 70 per cent of tax credit claimants are paid monthly or four weekly.<\/p>
<\/p>
We know that claimants are currently not getting all the entitlements for which they are eligible on legacy benefits. Requiring claimants to make a new Universal Credit claim will ensure that people will not miss out on any entitlements. This will result in an additional £2.4 billion going to 700,000 families who currently do not take up their full benefit entitlement.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4014", "label" : {"_value" : "Biography information for Sir Alok Sharma"} } , "answeringMemberConstituency" : {"_value" : "Reading West"} , "answeringMemberPrinted" : {"_value" : "Alok Sharma"} , "dateOfAnswer" : {"_value" : "2019-07-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-05T13:04:00.89Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "29"} , "answeringDeptShortName" : {"_value" : "Work and Pensions"} , "answeringDeptSortName" : {"_value" : "Work and Pensions"} , "date" : {"_value" : "2019-06-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Universal Credit"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Work and Pensions, what assessment she has made of the effect of the (a) wait for payment and (b) monthly payment of universal credit on the number of weeks of benefit paid annually to claimants compared with the number they were paid under their legacy benefits.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3976", "label" : {"_value" : "Biography information for Chris Williamson"} } , "tablingMemberConstituency" : {"_value" : "Derby North"} , "tablingMemberPrinted" : [{"_value" : "Chris Williamson"} ], "uin" : "270345"} , {"_about" : "http://data.parliament.uk/resources/1135182", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135182/answer", "answerText" : {"_value" : "
During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p>
- Seriously ill children likely to have a rare genetic disorder;<\/p>
- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p>
- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and acute myeloid leukaemia.<\/p>
<\/p>
WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.<\/p>
Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.<\/p>
WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:<\/p>
<\/p>
https://www.england.nhs.uk/publication/national-genomic-test-directories/<\/a><\/p> <\/p> The UK Genetic Testing Network (UKGTN) published the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing, which evaluated and recommended genetic tests for rare and inherited disorders for the National Health Service across the UK. However, there was not an equivalent for cancer genomic testing. The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test.<\/p> The National Genomic Test Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as WGS. As the price of WGS falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients.<\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-07-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "270282"}
, {"_value" : "270283"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-05T09:24:02.73Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Genomics: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, which diagnostic tests will whole genome sequencing replace, particularly for blood cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"}
}
, "tablingMemberConstituency" : {"_value" : "Sheffield South East"}
, "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"}
], "uin" : "270281"}
, {"_about" : "http://data.parliament.uk/resources/1135183", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1135183/answer", "answerText" : {"_value" : " During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p> - Seriously ill children likely to have a rare genetic disorder;<\/p> - People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p> - People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and acute myeloid leukaemia.<\/p> <\/p> WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.<\/p> Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.<\/p> WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:<\/p> <\/p> https://www.england.nhs.uk/publication/national-genomic-test-directories/<\/a><\/p> <\/p> The UK Genetic Testing Network (UKGTN) published the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing, which evaluated and recommended genetic tests for rare and inherited disorders for the National Health Service across the UK. However, there was not an equivalent for cancer genomic testing. The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test.<\/p> The National Genomic Test Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as WGS. As the price of WGS falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients.<\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2019-07-05", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "270281"}
, {"_value" : "270283"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-05T09:24:02.807Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-06-27", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Genetics: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the National Genomic Test Directory directly replaces the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/394", "label" : {"_value" : "Biography information for Mr Clive Betts"}
}
, "tablingMemberConstituency" : {"_value" : "Sheffield South East"}
, "tablingMemberPrinted" : [{"_value" : "Mr Clive Betts"}
], "uin" : "270282"}
, {"_about" : "http://data.parliament.uk/resources/1135184", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1135184/answer", "answerText" : {"_value" : " During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:<\/p> - Seriously ill children likely to have a rare genetic disorder;<\/p> - People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and<\/p> - People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS \u2013 children with cancer, sarcoma and acute myeloid leukaemia.<\/p> <\/p> WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.<\/p> Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.<\/p> WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:<\/p> <\/p>